Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company’s NaV1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biophar ...